These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445 [TBL] [Abstract][Full Text] [Related]
6. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303 [TBL] [Abstract][Full Text] [Related]
7. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Xu X; Williams JW; Gong H; Finnegan A; Chong AS Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024 [TBL] [Abstract][Full Text] [Related]
8. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. Cherwinski HM; McCarley D; Schatzman R; Devens B; Ransom JT J Pharmacol Exp Ther; 1995 Jan; 272(1):460-8. PubMed ID: 7529314 [TBL] [Abstract][Full Text] [Related]
9. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. Dimitrova P; Skapenko A; Herrmann ML; Schleyerbach R; Kalden JR; Schulze-Koops H J Immunol; 2002 Sep; 169(6):3392-9. PubMed ID: 12218161 [TBL] [Abstract][Full Text] [Related]
10. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Fukushima R; Kanamori S; Hirashiba M; Hishikawa A; Muranaka R; Kaneto M; Kitagawa H Toxicol Sci; 2009 Apr; 108(2):419-26. PubMed ID: 19190124 [TBL] [Abstract][Full Text] [Related]
11. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes. Miljkovic D; Samardzic T; Mostarica Stojkovic M; Stosic-Grujicic S; Popadic D; Trajkovic V Brain Res; 2001 Jan; 889(1-2):331-8. PubMed ID: 11166726 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Nair RV; Cao W; Morris RE Immunol Lett; 1995 Dec; 48(2):77-80. PubMed ID: 8719103 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Nair RV; Cao W; Morris RE Immunol Lett; 1995 Sep; 47(3):171-4. PubMed ID: 8747714 [TBL] [Abstract][Full Text] [Related]
15. Suppression of experimental autoimmune neuritis by leflunomide. Korn T; Toyka K; Hartung HP; Jung S Brain; 2001 Sep; 124(Pt 9):1791-802. PubMed ID: 11522581 [TBL] [Abstract][Full Text] [Related]
16. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion. Korn T; Magnus T; Toyka K; Jung S J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. Siemasko K; Chong AS; Jäck HM; Gong H; Williams JW; Finnegan A J Immunol; 1998 Feb; 160(4):1581-8. PubMed ID: 9469413 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Greene S; Watanabe K; Braatz-Trulson J; Lou L Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649 [TBL] [Abstract][Full Text] [Related]
19. Regulation of B cell function by the immunosuppressive agent leflunomide. Siemasko KF; Chong AS; Williams JW; Bremer EG; Finnegan A Transplantation; 1996 Feb; 61(4):635-42. PubMed ID: 8610393 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Silva HT; Cao W; Shorthouse RA; Löffler M; Morris RE Transplant Proc; 1997; 29(1-2):1292-3. PubMed ID: 9123312 [No Abstract] [Full Text] [Related] [Next] [New Search]